Project Progress

Important Milestones:

Month 3: Representative cytostatic drugs to be studied were selected (WP8, M 15)
Month 12: Validated analytical methods (LC, GC) for the determination of the selected model compounds were developed (WP2; M4)
Month 16: Results from acute tests, that are needed for establishing dose ranges for chronic exposure tests completed (WP5; M8).
Month 18: Cytotoxicity of cytostatic drugs determined & dose ranges for further genotoxicity and gene expression in vitro studies were established (WP6; M10)
Month 24: Predictive transcript signature database for 5-FU is established (WP7; M13)
Month 30: PHARMAS Cluster Conference organised
Month 40: All environmental samples collected and distributed to the partners for chemical and toxicological analyses (WP3; M5)

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.

I accept cookies from this site.

EU Cookie Directive Module Information